Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Molecular Targeted Agents / Immunotherapy / Biologics

110 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED12112

01/04/2013

NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma

VICCBMT1501

04/22/2015

A Multicenter OpenLabel Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCBMT1427

03/23/2015

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Solid Tumors

COGACCL0922

02/20/2013

SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

PRECOGHEM0901

12/04/2012

Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHN13108

05/22/2015

A Randomized Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin with Concurrent Radiation Therapy Followed by Consolidation in Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBREP14115

05/21/2015

An Open-Label, Phase I Study of SRN-927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

VICCHEMP14114

05/20/2015

A Phase 1, Open-label, Multicenter, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1505

05/06/2015

An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1486

05/01/2015

A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Uveal Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1499

04/23/2015

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN14121

04/23/2015

A Phase II Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Molecular Targeted Agents / Immunotherapy / Biologics

Gastric/Gastroesophageal

VICCGI1481

04/22/2015

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1482

04/22/2015

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN14108

04/09/2015

A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1490

04/07/2015

Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation

Molecular Targeted Agents / Immunotherapy / Biologics

VICCTHO1493

04/02/2015

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1480

03/31/2015

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL14106

03/25/2015

A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder

VICCURO14100

03/24/2015

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1246

03/13/2015

Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1466

03/12/2015

Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroendocrine
Pancreatic

ECOGGIE2211

03/04/2015

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1413

03/02/2015

A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination with GSK2141795 in Patients with Advanced Uveal Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma

VICCHEM1378

02/27/2015

A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Sarcoma

VICCSAR1483

02/26/2015

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1471

02/04/2015

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

VICCGI1497

01/27/2015

A Multi-Institutional, Single-Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCPHI13113

01/22/2015

A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors.

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1213

01/16/2015

Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204) with or without Bevacizumab in Patients with Stage IV BRAFV600 Mutant Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1473

01/09/2015

A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1384

12/18/2014

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1417

12/17/2014

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Rectal

VICCGI13102

12/09/2014

A Phase II Study of Panitumumab in Combination with FOLFIRI after Progression on FOLFIRI plus Bevacizumab in KRAS and NRAS Wild Type Metastatic Colorectal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Kidney (Renal Cell)

VICCUROP1468

12/04/2014

A Phase 1b, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination with MK-3475 in Patients with Advanced Renal Cell Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1463

11/18/2014

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom's Macroglobulinemia

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1453

11/18/2014

A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Molecular Targeted Agents / Immunotherapy / Biologics

Myelodysplastic Syndrome

VICCHEM1487

11/10/2014

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Molecular Targeted Agents / Immunotherapy / Biologics

Urologic

VICCPHI1449

10/27/2014

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Lymphoma

COGANHL12P1

10/20/2014

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1467

10/02/2014

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1432

09/19/2014

A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1358

09/15/2014

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1402

09/15/2014

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHN13111

08/27/2014

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1415

08/27/2014

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Sarcoma

VICCSAR1419

08/27/2014

A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1450

08/13/2014

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1444

08/05/2014

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-Line Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1429

08/05/2014

An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1435

07/31/2014

First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced Stage Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN1332

07/18/2014

A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN1433

07/16/2014

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Rectal

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI13100

06/10/2014

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1387

05/28/2014

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients with Locally Advanced or Metastatic Cancers with Mutant KRAS

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma
Neuro-Oncology

VICCMEL1398

05/23/2014

BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation- Positive Melanoma that has Metastasized to the Brain

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1411

05/22/2014

A Phase 1b Study of LY2835219 in Combination with Endocrine Therapies for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

VICCMD13112

05/19/2014

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1375

05/16/2014

Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies BVD-523-01

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM13110

04/11/2014

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM13106

04/09/2014

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic

VICCHEM1274

03/31/2014

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMELP1388

03/24/2014

A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBREP1363

03/21/2014

A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN12106

03/12/2014

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma
Multiple Myeloma

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder

VICCURO1382

02/10/2014

A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic
Leukemia

VICCHEM1346

01/21/2014

A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female
Breast - Male

ECOGBRES1207

10/31/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1255

09/28/2013

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Thyroid

VICCTHN1318

09/19/2013

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1284

06/05/2013

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1304

06/04/2013

A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE12101

04/04/2013

A Phase Ib Trial of BYL719 (an a-Specific PI3K Inhibitor) in Combination with Endocrine Therapy in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBREP12116

03/25/2013

An Open-Label, Phase I/IIa Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1260

03/19/2013

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal

VICCGI1211

03/08/2013

Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1256

12/06/2012

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1146

08/14/2012

Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Molecular Targeted Agents / Immunotherapy / Biologics

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

COGACNS0821

10/08/2011

ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

ECOGTHNE5508

06/29/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

VICCRAD1060

02/15/2011

A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients with 1-4 Brain Metastases

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Molecular Targeted Agents / Immunotherapy / Biologics

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGHNE1305-M

02/11/2009

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)